Technical Analysis for ROIV - Roivant Sciences Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 2.00% | |
| Oversold Stochastic | Weakness | 2.00% | |
| Bullish Engulfing | Bullish | 3.63% | |
| Crossed Above 200 DMA | Bullish | 3.63% | |
| Lower Bollinger Band Walk | Weakness | 3.63% | |
| Lower Bollinger Band Touch | Weakness | 3.63% | |
| Oversold Stochastic | Weakness | 3.63% | |
| Fell Below 200 DMA | Bearish | 5.02% | |
| NR7 | Range Contraction | 5.02% | |
| Lower Bollinger Band Walk | Weakness | 5.02% |
| Alert | Time |
|---|---|
| Gapped Up (Full) | 3 minutes ago |
| Rose Above 20 DMA | 3 minutes ago |
| Rose Above Previous Day's High | 3 minutes ago |
| Rose Above 50 DMA | 3 minutes ago |
| Rose Above 10 DMA | 3 minutes ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Autoimmune Disease Antibodies Inflammation Monoclonal Antibodies Psoriasis Ulcerative Colitis Abdominal Pain Atopic Dermatitis Crohn's Disease Treatment Of Psoriasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Autoimmune Disease Antibodies Inflammation Monoclonal Antibodies Psoriasis Ulcerative Colitis Abdominal Pain Atopic Dermatitis Crohn's Disease Treatment Of Psoriasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.055 |
| 52 Week Low | 8.611 |
| Average Volume | 6,230,038 |
| 200-Day Moving Average | 11.21 |
| 50-Day Moving Average | 11.69 |
| 20-Day Moving Average | 11.65 |
| 10-Day Moving Average | 11.58 |
| Average True Range | 0.30 |
| RSI (14) | 47.09 |
| ADX | 12.56 |
| +DI | 20.76 |
| -DI | 23.68 |
| Chandelier Exit (Long, 3 ATRs) | 11.21 |
| Chandelier Exit (Short, 3 ATRs) | 11.95 |
| Upper Bollinger Bands | 12.08 |
| Lower Bollinger Band | 11.21 |
| Percent B (%b) | 0.32 |
| BandWidth | 7.48 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0449 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.90 | ||||
| Resistance 3 (R3) | 11.86 | 11.69 | 11.83 | ||
| Resistance 2 (R2) | 11.69 | 11.58 | 11.71 | 11.81 | |
| Resistance 1 (R1) | 11.59 | 11.52 | 11.64 | 11.63 | 11.79 |
| Pivot Point | 11.41 | 11.41 | 11.44 | 11.43 | 11.41 |
| Support 1 (S1) | 11.31 | 11.31 | 11.36 | 11.35 | 11.19 |
| Support 2 (S2) | 11.14 | 11.24 | 11.16 | 11.17 | |
| Support 3 (S3) | 11.04 | 11.14 | 11.15 | ||
| Support 4 (S4) | 11.08 |
